Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INM004 in Pediatric STEC-HUS
NCT06389474Phase 3Recruiting
- Sponsor
- Inmunova
- Start
- Oct 2024
- Primary completion
- Aug 2026
- Modality
- Fab Fragments
- Countries
- 9
01
Overview
A Phase 3 trial of equine immunoglobulin F(ab')2 fragments targeting Shiga toxin in hemolytic uremic syndrome (HUS), sponsored by Inmunova. Started Oct 2024; status: recruiting.
02
Drugs
equine immunoglobulin F(ab')2 fragments targeting Shiga toxin
03
Conditions
hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on NCT06389474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389474.